In this study, while the incidence of paradoxical eczema in biologic-treated patients with psoriasis was low overall, it was highest in those receiving IL-17 inhibitors followed by those receiving TNF inhibitors, those receiving IL-12/23 inhibitors, and those receiving IL-23 inhibitors. Here, IL17A is linked to psoriasis.